Figure 4 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer
<p>Disease-free survival and overall survival in patients who extended therapy and those who did not. <b>A</b> and <b>B,</b> Disease-free survival (<b>A</b>) and overall survival (<b>B</b>). Note: HR was adjusted for age at diagnosis, calendar pe...
Furkejuvvon:
| Váldodahkki: | Erwei Zeng (14958443) (author) |
|---|---|
| Eará dahkkit: | Wei He (14958446) (author), Arvid Sjölander (14958449) (author), Jenny Bergqvist (14958452) (author), Kamila Czene (14958455) (author) |
| Almmustuhtton: |
2025
|
| Fáttát: | |
| Fáddágilkorat: |
Lasit fáddágilkoriid
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|
Geahča maid
-
Figure 1 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer
Dahkki: Erwei Zeng (14958443)
Almmustuhtton: (2025) -
Figure 2 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer
Dahkki: Erwei Zeng (14958443)
Almmustuhtton: (2025) -
Figure 3 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer
Dahkki: Erwei Zeng (14958443)
Almmustuhtton: (2025) -
Table 1 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer
Dahkki: Erwei Zeng (14958443)
Almmustuhtton: (2025) -
Figure 1 from Reduction in Vaccine HPV Type Infections in a Young Women Group (18–25 Years) Five Years after HPV Vaccine Introduction in Colombia
Dahkki: Alba L. Combita (22677298)
Almmustuhtton: (2025)